Liver Cancer
Liver Cancer
Advertisement
Richard S. Finn, MDLiver Cancer | June 3, 2025
Dr. Finn discusses the follow-up of LEAP-002 and its clinical implications despite not meeting the primary end points.
Emily MenendezLiver Cancer | May 29, 2025
The addition of concurrent chemoradiation to chemotherapy can improve OS and resection rates in patients with LAGBC.
Zachary BessetteLiver Cancer | May 29, 2025
LEAP-002 long-term follow-up suggests there may be benefit associated with len/pembro for patients with aHCC.
Dina Ioffe, MDLiver Cancer | May 29, 2025
Dina Ioffe, MD, Fox Chase Cancer Center, talks about the use of immunotherapy in the neoadjuvant or adjuvant setting.
Jessica GangaLiver Cancer | May 28, 2025
Researchers evaluated the efficacy and safety of hepatic arterial infusion chemotherapy as a first-line treatment option.
Christopher Lieu, MDLiver Cancer | May 16, 2025
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Maen Abdelrahim, MD, PhDLiver Cancer | April 22, 2025
Dr. Maen Abdelrahim reflects on the multidisciplinary collaboration required to make transplant oncology a clinical reality.
Leah LawrenceLiver Cancer | April 8, 2025
GI Oncology Now spoke with experts about HCC, how its management is changing, and how advancements are reshaping the disease.
Emily MenendezLiver Cancer | March 14, 2025
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
Richard S. Finn, MDLiver Cancer | February 7, 2025
Drs. Finn and Yopp discuss the challenges of defining high-risk patient populations in adjuvant therapy trials for HCC.
Christopher Lieu, MDLiver Cancer | February 6, 2025
Nivolumab plus ipilimumab provided a higher OS and ORR rate, supporting the combination as a potential standard of care.
Boris Pasche, MD, PhDLiver Cancer | January 28, 2025
Dr. Pasche discusses the trial that led to the TheraBionic P1 device's regulatory approval by the FDA.
Benjamin Weinberg, MD, FACPLiver Cancer | January 27, 2025
Dr. Weinberg provided his perspective on the CheckMate 9DW expanded analyses, as well as multiple studies in CRC.
Emily MenendezLiver Cancer | January 24, 2025
Previous data pointed to the benefit of adjuvant immunotherapy for patients with HCC through the use of CIK cells.
Christopher Lieu, MDLiver Cancer | January 24, 2025
Dr. Lieu details practice-changing studies from ASCO GI 2025, including CheckMate-9DW, CheckMate 8HW, and BREAKWATER.
Emily MenendezLiver Cancer | January 23, 2025
In EMERALD-1, investigators analyzed the combination of durvalumab plus bevacizumab and TACE versus placebo with TACE.
Zachary BessetteLiver Cancer | January 23, 2025
Additional analyses from the CheckMate 9DW study shed further light on the clinical efficacy and safety of ipi/nivo for uHCC.
Brandon TwyfordLiver Cancer | January 23, 2025
The study reinforces the potential of triplet blockade with casdozo, atezo, and bev as a viable approach for managing uHCC.
Richard S. Finn, MDLiver Cancer | January 22, 2025
Dr. Finn previews key abstracts in liver cancer and other hepatobiliary malignancies from ASCO GI 2025.
Brandon TwyfordLiver Cancer | January 22, 2025
Trial results show no significant benefit of adding chemoradiation to adjuvant chemotherapy in resected gallbladder cancer.
Advertisement